Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group

Marco Benasso, Anna Ponzanelli, Marco Merlano, Gianmauro Numico, Isabella Ricci, Viviana Vigo, Francesco Grossi, Dino Amadori, Giovanna Cavallo, Barbara Capaccetti, Paola Taveggia, Luca Boni, Riccardo Rosso

Research output: Contribution to journalArticle

Abstract

The aim of this multicenter trial was to test the feasibility and the activity of a three-drug combination where paclitaxel is added to cisplatin and 5-fluorouracil. Patients with metastatic or relapsed SCC-HN unsuitable for further locoregional radical treatment, not previously treated with chemotherapy, were eligible to receive paclitaxel 160 mg/m2 (3-hr infusion) day 1, CDDP 25 mg/m2/day and 5-FU 250 mg/m2/day bolus on days 1, 2, 3 every three weeks up to a maximum of five courses. Fourty-seven patients were enrolled by five Institutions in Italy. Main grade III-IV toxicities were: neutropenia (48%), thrombocytopenia (6%), anemia (4%), diarrhea (2%), mucositis (2%). Six patients had a complete response (13.3%) and eight a partial response (17.8%). Median progression free survival and overall survival are 4.1 and 7.9 months. One-year progression free survival and overall survival are 16% and 29%. This three-drug regimen has an excellent safety profile. The activity in the palliation of recurrent SCC-HN, however, does not appear to be improved in comparison with cisplatin and 5-fluorouracil or cisplatin and paclitaxel regimens. Recent studies indicate a more promising role of taxanes including triplets in the induction therapy of previously untreated patients.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalActa Oncologica
Volume45
Issue number2
DOIs
Publication statusPublished - Mar 2006

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group'. Together they form a unique fingerprint.

  • Cite this

    Benasso, M., Ponzanelli, A., Merlano, M., Numico, G., Ricci, I., Vigo, V., Grossi, F., Amadori, D., Cavallo, G., Capaccetti, B., Taveggia, P., Boni, L., & Rosso, R. (2006). Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group. Acta Oncologica, 45(2), 168-174. https://doi.org/10.1080/02841860500468919